Company intelligence / Profile preview

Pglchem

Ownership: Private
Development stage: Preclinical

Overview

Pglchem supplies a wide range of nootropics and research chemicals globally. There are no clinical results reported as the company does not develop drugs through clinical trials.

Therapeutic areas: Neurology
Modalities: Small moleculePeptidesSynthetic compound
Industry: Chemicals & Materials

Drug pipeline

1 asset

PGL-36

Pre-clinical

Indications: Autoimmune diseases, Depression

Beyond the preview

Go deeper on Pglchem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pglchem.

Explore the full profile